Please use this identifier to cite or link to this item:
Title: Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand.
Authors: Hantrakun, Viriya
Chierakul, Wirongrong
Chetchotisakd, Ploenchan
Anunnatsiri, Siriluck
Currie, Bart J
Peacock, Sharon J
Day, Nicholas P J
Cheah, Phaik Yeong
Cheah, Phaik
Limmathurotsakul, Direk
Lubell, Yoel
Citation: Transactions of the Royal Society of Tropical Medicine and Hygiene 2015-06; 109(6): 416-8
Abstract: Melioidosis is a common community-acquired infectious disease in northeast Thailand associated with overall mortality of approximately 40% in hospitalized patients, and over 70% in severe cases. Ceftazidime is recommended for parenteral treatment in patients with suspected melioidosis. Meropenem is increasingly used but evidence to support this is lacking. A decision tree was used to estimate the cost-effectiveness of treating non-severe and severe suspected acute melioidosis cases with either ceftazidime or meropenem. Empirical treatment with meropenem is likely to be cost-effective providing meropenem reduces mortality in severe cases by at least 9% and the proportion with subsequent culture-confirmed melioidosis is over 20%. In this context, treatment of severe cases with meropenem is likely to be cost-effective, while the evidence to support the use of meropenem in non-severe suspected melioidosis is not yet available.
Click to open PubMed article:
Click to open Pubmed Article:
Journal title: Transactions of the Royal Society of Tropical Medicine and Hygiene
Publication Date: 2015-06
Type: Journal Article
Research Support, Non-U.S. Gov't
DOI: 10.1093/trstmh/trv002
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.

Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing


PubMed References

Who's citing